Keeping Track: Approvals Aplenty As FDA Clears Taltz, Cinqair And Anthim
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Deal Watch: Roche, Pfizer, GSK Close Out 2021 With Licensing Transactions
Ahead of the usual flurry of deal-making in January, Roche gets retinal cell therapy candidate from Lineage Cell Therapeutics, Pfizer subsidiary Amplyx licenses antiviral candidate to Vera, and GSK expands neurology tie-up with Ligand.
Keeping Track: FDA Nixes Medicure’s Aggrastat For STEMI, Approves Insys’ Syndros
The latest drug development news and highlights from our FDA Performance Tracker
Lilly’s Psoriasis Drug Taltz Set For Second Quarter Launch
Ixekizumab had a smooth FDA approval, with no advisory committee needed for the second member of the IL-17 inhibitor class.